CCLA Investment Management Grows Position in Agilent Technologies, Inc. $A

CCLA Investment Management boosted its holdings in Agilent Technologies, Inc. (NYSE:A) by 31.7% in the 2nd quarter, HoldingsChannel reports. The fund owned 930,658 shares of the medical research company’s stock after acquiring an additional 223,987 shares during the quarter. CCLA Investment Management’s holdings in Agilent Technologies were worth $109,771,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the business. Vanguard Group Inc. raised its position in Agilent Technologies by 0.7% in the first quarter. Vanguard Group Inc. now owns 33,408,626 shares of the medical research company’s stock worth $3,908,141,000 after acquiring an additional 240,965 shares in the last quarter. Pictet Asset Management Holding SA grew its holdings in Agilent Technologies by 2.5% in the first quarter. Pictet Asset Management Holding SA now owns 5,341,870 shares of the medical research company’s stock valued at $624,888,000 after purchasing an additional 128,131 shares during the last quarter. Generation Investment Management LLP grew its holdings in Agilent Technologies by 19.8% in the first quarter. Generation Investment Management LLP now owns 4,983,556 shares of the medical research company’s stock valued at $582,976,000 after purchasing an additional 824,243 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Agilent Technologies by 18.7% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,836,105 shares of the medical research company’s stock valued at $448,748,000 after purchasing an additional 604,124 shares during the last quarter. Finally, Nordea Investment Management AB grew its holdings in Agilent Technologies by 16.2% in the second quarter. Nordea Investment Management AB now owns 3,213,748 shares of the medical research company’s stock valued at $383,143,000 after purchasing an additional 447,207 shares during the last quarter.

Agilent Technologies Stock Up 0.4%

A opened at $148.03 on Monday. The company has a quick ratio of 1.71, a current ratio of 2.25 and a debt-to-equity ratio of 0.53. The firm has a market cap of $41.97 billion, a P/E ratio of 34.75, a PEG ratio of 4.83 and a beta of 1.26. Agilent Technologies, Inc. has a 52 week low of $96.43 and a 52 week high of $153.84. The business’s fifty day simple moving average is $130.39 and its 200 day simple moving average is $119.43.

Agilent Technologies (NYSE:A) last posted its quarterly earnings data on Wednesday, August 27th. The medical research company reported $1.37 EPS for the quarter, meeting analysts’ consensus estimates of $1.37. The business had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.67 billion. Agilent Technologies had a return on equity of 25.51% and a net margin of 17.97%.The business’s revenue for the quarter was up 10.1% compared to the same quarter last year. During the same quarter last year, the company earned $1.32 earnings per share. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. As a group, equities research analysts anticipate that Agilent Technologies, Inc. will post 5.58 EPS for the current fiscal year.

Agilent Technologies Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, October 22nd. Shareholders of record on Tuesday, September 30th were paid a $0.248 dividend. This represents a $0.99 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date of this dividend was Tuesday, September 30th. Agilent Technologies’s dividend payout ratio (DPR) is presently 23.24%.

Analyst Ratings Changes

Several analysts have weighed in on the company. Evercore ISI upped their target price on Agilent Technologies from $128.00 to $140.00 and gave the company an “in-line” rating in a report on Tuesday, October 7th. TD Cowen upped their target price on Agilent Technologies from $150.00 to $162.00 and gave the company a “buy” rating in a report on Tuesday, October 14th. UBS Group raised Agilent Technologies from a “neutral” rating to a “buy” rating and upped their target price for the company from $130.00 to $170.00 in a report on Wednesday, October 8th. Barclays upped their target price on Agilent Technologies from $125.00 to $150.00 and gave the company an “equal weight” rating in a report on Thursday, October 2nd. Finally, Wells Fargo & Company upped their target price on Agilent Technologies from $140.00 to $150.00 and gave the company an “overweight” rating in a report on Monday, September 15th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $149.62.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.